


## TMX-201

|                           |  |
|---------------------------|--|
| <b>Cat. No.:</b>          | HY-150158  |
| <b>CAS No.:</b>           | 1149339-78-5   |
| <b>Molecular Formula:</b> | C <sub>57</sub> H <sub>93</sub> N <sub>6</sub> O <sub>12</sub> P   |
| <b>Molecular Weight:</b>  | 1085.36  |
| <b>Target:</b>            | Toll-like Receptor (TLR)   |
| <b>Pathway:</b>           | Immunology/Inflammation  |
| <b>Storage:</b>           | 4°C, sealed storage, away from moisture and light<br>* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 50 mg/mL (46.07 mM); ultrasonic and warming and heat to 60°C)

| Concentration | Mass      |           |           |
|---------------|-----------|-----------|-----------|
|               | 1 mg      | 5 mg      | 10 mg     |
| 1 mM          | 0.9214 mL | 4.6068 mL | 9.2135 mL |
| 5 mM          | 0.1843 mL | 0.9214 mL | 1.8427 mL |
| 10 mM         | 0.0921 mL | 0.4607 mL | 0.9214 mL |

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

TLR7

#### In Vitro

TMX-201 is more potent cytokine inducer than [Imiquimod](#) (HY-B0180) in both mouse and human mononuclear cells. TMX-201 shows less off-target binding compared to Imiquimod<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

The maximum tolerated dose of TMX-201 by i.v. administration is 75 mg/kg<sup>[1]</sup>.

TMX-201 (4mg/kg, IP) suppresses the growth of established subcutaneous B16 melanoma by 46%, without discernible adverse effects<sup>[1]</sup>.

TMX-201 (IP or intra-tumor administration), in combination with anti-CTLA4 antibody, significantly suppressed lung metastasis formation in the 4T1 breast cancer model<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

[1]. Dennis A. Carson, et al. Application of novel phospholipid conjugated Toll like receptor 7 ligands for cancer therapy by topical and systemic administration. Cancer Res 2014;74(19 Suppl): 2568.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA